These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 24510314

  • 1. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
    Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.
    Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
    Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, Goitein G, Zografos L, Leyvraz S.
    Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
    [Abstract] [Full Text] [Related]

  • 3. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients.
    Egerer G, Lehnert T, Max R, Naeher H, Keilholz U, Ho AD.
    Int J Clin Oncol; 2001 Feb; 6(1):25-8. PubMed ID: 11706523
    [Abstract] [Full Text] [Related]

  • 4. Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study.
    Farolfi A, Ridolfi L, Guidoboni M, Milandri C, Calzolari F, Scarpi E, Amadori D, Ridolfi R.
    J Chemother; 2011 Oct; 23(5):300-5. PubMed ID: 22005064
    [Abstract] [Full Text] [Related]

  • 5. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
    Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S.
    Ann Oncol; 2006 Apr; 17(4):578-83. PubMed ID: 16469752
    [Abstract] [Full Text] [Related]

  • 6. Treatment of metastatic uveal melanoma with intravenous fotemustine.
    Spagnolo F, Grosso M, Picasso V, Tornari E, Pesce M, Queirolo P.
    Melanoma Res; 2013 Jun; 23(3):196-8. PubMed ID: 23624366
    [Abstract] [Full Text] [Related]

  • 7. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy.
    Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L.
    J Clin Oncol; 1997 Jul; 15(7):2589-95. PubMed ID: 9215829
    [Abstract] [Full Text] [Related]

  • 8. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
    Khayat D, Cour V, Bizzari JP, Aigner K, Borel C, Cohen-Alloro G, Weil M, Auclerc G, Buthiau D, Bousquet JC.
    Am J Clin Oncol; 1991 Oct; 14(5):400-4. PubMed ID: 1951178
    [Abstract] [Full Text] [Related]

  • 9. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.
    Schuster R, Lindner M, Wacker F, Krössin M, Bechrakis N, Foerster MH, Thiel E, Keilholz U, Schmittel A.
    Melanoma Res; 2010 Jun; 20(3):191-6. PubMed ID: 20335820
    [Abstract] [Full Text] [Related]

  • 10. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
    Siegel R, Hauschild A, Kettelhack C, Kähler KC, Bembenek A, Schlag PM.
    Eur J Surg Oncol; 2007 Jun; 33(5):627-32. PubMed ID: 17196362
    [Abstract] [Full Text] [Related]

  • 11. [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
    Cui CL, Chi ZH, Yuan XQ, Lian HY, Si L, Guo J.
    Ai Zheng; 2008 Aug; 27(8):845-50. PubMed ID: 18710619
    [Abstract] [Full Text] [Related]

  • 12. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
    Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB.
    Br J Cancer; 2002 Oct 07; 87(8):840-5. PubMed ID: 12373596
    [Abstract] [Full Text] [Related]

  • 13. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
    Fety R, Lucas C, Solere P, Cour V, Vignoud J.
    Cancer Chemother Pharmacol; 1992 Oct 07; 31(2):118-22. PubMed ID: 1451232
    [Abstract] [Full Text] [Related]

  • 14. Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
    Niederkorn A, Wackernagel W, Artl M, Schwantzer G, Aigner B, Richtig E.
    Acta Ophthalmol; 2014 Dec 07; 92(8):e696-7. PubMed ID: 24774993
    [No Abstract] [Full Text] [Related]

  • 15. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y.
    J Clin Oncol; 2004 Mar 15; 22(6):1118-25. PubMed ID: 15020614
    [Abstract] [Full Text] [Related]

  • 16. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy.
    Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, Pouillart P, Schlienger P, Servois V, Asselain B.
    Eur J Surg Oncol; 1998 Apr 15; 24(2):127-30. PubMed ID: 9591028
    [Abstract] [Full Text] [Related]

  • 17. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
    Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Nguyen BB, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre J, de Gislain C, Bensadoun JR, Clavel M.
    Cancer Radiother; 2003 Feb 15; 7(1):1-8. PubMed ID: 12648711
    [Abstract] [Full Text] [Related]

  • 18. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M.
    Lancet Oncol; 2012 Sep 15; 13(9):879-86. PubMed ID: 22894884
    [Abstract] [Full Text] [Related]

  • 19. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU, Wenzel E, Brassow FW, Berger J, Breitbart EW, Teichmann W.
    Cancer Chemother Pharmacol; 1991 Sep 15; 29(1):85-7. PubMed ID: 1742855
    [Abstract] [Full Text] [Related]

  • 20. Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion.
    Ludwig JM, Haubold J, Bauer S, Richly H, Siveke JT, Wimmer J, Umutlu L, Schaarschmidt BM, Theysohn JM.
    Radiol Oncol; 2021 May 31; 55(3):347-353. PubMed ID: 34051707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.